Sign Out
Asthma: SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older.
Exercise-Induced Bronchoconstriction (EIB): SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older.
Allergic Rhinitis: SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Neuropsychiatric Events under Precautions], reserve use for patients who have an inadequate response or intolerance to alternative therapies.
Limitations of Use: SINGULAIR is not indicated for the treatment of an acute asthma attack.
